NIH funded a $4 million, five-year study at UTHealth Houston to investigate why weight returns after stopping GLP-1 receptor agonist therapy. The project is led by principal investigator Absalon and is designed to clarify biological and behavioral mechanisms behind post-discontinuation regain. The announcement points to a growing evidence gap: while GLP-1s improve weight loss during treatment, real-world continuity decisions and adherence pressures create outcomes that differ from controlled continuation studies. For the biotech sector, the grant signals that mechanism-focused work tied to adherence and discontinuation could influence future trial endpoints, labeling, and next-generation formulations intended to improve long-term outcomes after stopping or changing dosing.